ReviewCurrent opinion in lipidology2004
Electronegative low-density lipoprotein.
Review in Current opinion in lipidology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00988364 (Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome
Who cites it
39 citing papers in PubMed, 138 citations in OpenAlex.
- Effects of proanthocyanidin on oxidative stress biomarkers and adipokines in army cadets: a placebo-controlled, double-blind study.European journal of nutrition · 2017Trial
- We Must Abandon the Myth: Oxidized Low-density Lipoprotein is not a Lipoprotein that Plays a Key Role in Atherogenesis.Current medicinal chemistry · 2025Review
- Atherogenic circulating lipoproteins in ischemic stroke.Frontiers in cardiovascular medicine · 2024Review
- Special Issue: New Insight into the Molecular Role of Lipids and Lipoproteins in Vascular Diseases.International journal of molecular sciences · 2023Article
- Can Electronegative LDL Act as a Multienzymatic Complex?International journal of molecular sciences · 2023Review
- The Oxidized Lipoproteins In Vivo: Its Diversity and Behavior in the Human Circulation.International journal of molecular sciences · 2023Review
- Presence of Ceramidase Activity in Electronegative LDL.International journal of molecular sciences · 2022Article
- Heparin binding triggers human VLDL remodeling by circulating lipoprotein lipase: Relevance to VLDL functionality in health and disease.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022Article
- Review
- Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies.Journal of clinical medicine · 2021Review
- Changes in the Composition and Function of Lipoproteins after Bariatric Surgery in Patients with Severe Obesity.Journal of clinical medicine · 2021Article
- Molecular and Cellular Mechanisms of Electronegative Lipoproteins in Cardiovascular Diseases.Biomedicines · 2020Review
- Combined LDL and VLDL Electronegativity Correlates with Coronary Heart Disease Risk in Asymptomatic Individuals.Journal of clinical medicine · 2019Article
- Association between Negatively Charged Low-Density Lipoprotein L5 and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients.Journal of clinical medicine · 2019Article
- Electronegative LDL from Rabbits Fed with Atherogenic Diet Is Highly Proinflammatory.Mediators of inflammation · 2019Article
- Oxidized and electronegative low-density lipoprotein as potential biomarkers of cardiovascular risk in obese adolescents.Clinics (Sao Paulo, Brazil) · 2018Article
- Electronegative Low-Density Lipoprotein L5 Impairs Viability and NGF-Induced Neuronal Differentiation of PC12 Cells via LOX-1.International journal of molecular sciences · 2017Article
- Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation.Biochimica et biophysica acta · 2016Article
- Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.International journal of molecular sciences · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe occurrence in blood of an electronegatively charged LDL was described in 1988. During the 1990s reports studying electronegative LDL (LDL(-)) were scant and its atherogenic role controversial. Nevertheless, recent reports have provided new evidence on a putative atherogenic role of LDL(-). This review focuses on and discusses these new findings. RECENT
findingsIn recent years, LDL(-) has been found to be involved in several atherogenic features through its action on cultured endothelial cells. LDL(-) induces the production of chemokines, such as IL-8 and monocyte chemotactic protein 1, and increases tumor necrosis factor-alpha-induced production of vascular cell adhesion molecule 1, with these molecules being involved in early phases of leukocyte recruitment. LDL(-) from familial hypercholesterolemic patients also decreases DNA synthesis and intracellular fibroblast growth factor 2 production, which may contribute to impaired angiogenesis and increased apoptosis. In addition, the preferential association of platelet-activating factor acetylhydrolase with LDL(-) has been reported, suggesting a proinflammatory role of this enzyme in LDL(-). SUMMARY: Recent findings suggest that LDL(-) could contribute to atherogenesis via several mechanisms, including proinflammatory, proapoptotic and anti-angiogenesis properties. Further studies are required to define the role of LDL(-) in atherogenesis more precisely and to clarify mechanisms involved in endothelial cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.